Created in partnership with dermatology experts for dermatology experts, this is your one-stop educational resource for the latest information on BIMZELX—delivered by leading experts you trust.

Check back often, as we will continually share new details about BIMZELX.

BIMZELX rapid response video for HCPs — Dr. Craig Leonardi speaking to the camera. The words, “Rapid and sustained skin clearance” appear onscreen.

Treatment Response Time

Learn how you can give many of your patients the opportunity to achieve skin clearance that can last.

Watch video

BIMZELX complete clearance video for HCPS — Dr. Alice Gottlieb speaking to the camera. The words, “complete clearance for more patients” are onscreen.

Complete Clearance

Find out how BIMZELX can help many patients achieve PASI 100.

Watch video

BIMZELX head-to-head video for HCPS — Dr. Bruce Strober speaking to the camera. BIMZELX logo and words, “compared to COSENTYX, HUMIRA and STELARA” are onscreen.


Hear how BIMZELX performed in clinical trials against three of the most prescribed biologics.

Watch video

BIMZELX IL-17A + IL-17F targeting video for HCPs — Dr. Andy Blauvelt speaking to the camera. The words, “Why IL-17F is significant” and “Why BIMZELX® is different” are onscreen.

Targeting IL-17A and IL-17F

Discover the significance of IL-17F in psoriasis pathogenesis.

Watch video

UCB leadership video about BIMZELX for HCPs — two women and two men from the UCB leadership team standing and speaking to the camera.

UCB Leadership

Hear from UCB leaders as they discuss how patients are the catalyst for psoriasis research.

Watch video

BIMZELX orgin video for HCPs — the BIMZELX logo and the words, “The journey to discovery from the 'grandfather' of BIMZELX" are onscreen.

BIMZELX: The Discovery

Learn the story behind BIMZELX from Dr. Stevan Shaw, VP, Head of Immunology Research for UCB.

Watch video

Dr. Jeffrey Weinberg investigator video for HCPs

Investigator Experience-Jeffrey Weinberg, MD

Clinical trial investigator Jeffrey Weinberg, MD, of Infinity Dermatology NYC and Mt. Sinai, discusses his experience with BIMZELX.

Watch video

Dr. Jaime Weisman investigator video for HCPs

Investigator Experience-Jamie Weisman, MD

Clinical trial investigator Jamie Weisman, MD, of Atlanta Medical Dermatology Specialists, Inc., discusses her experience with BIMZELX.

Watch video


What’s the BIMZELX story? It‘s actually layered, with each chapter building on the last. See the MOA narrative—and find out what makes BIMZELX different from other biologics.

BIMZELX MOA video for HCPs

©2024 UCB, Inc., Smyrna, GA 30080. All rights reserved

04/2024 US-BK-2400403



View Efficacy

*From the very first dose as measured at Week 4;
results were not immediate.


Get updates and contact a sales representative


Suicidal Ideation and Behavior

BIMZELX® (bimekizumab-bkzx) may increase the risk of suicidal ideation and behavior (SI/B). A causal association between treatment with BIMZELX and increased risk of SI/B has not been established. Prescribers should weigh the potential risks and benefits before using BIMZELX in patients with a history of severe depression or SI/B. Advise monitoring for the emergence or worsening of depression, suicidal ideation, or other mood changes. If such changes occur, advise to promptly seek medical attention, refer to a mental health professional as appropriate, and re-evaluate the risks and benefits of continuing treatment.


BIMZELX may increase the risk of infections. Do not initiate treatment with BIMZELX in patients with any clinically important active infection until the infection resolves or is adequately treated. In patients with a chronic infection or a history of recurrent infection, consider the risks and benefits prior to prescribing BIMZELX. Instruct patients to seek medical advice if signs or symptoms suggestive of clinically important infection occur. If a patient develops such an infection or is not responding to standard therapy, monitor the patient closely and do not administer BIMZELX until the infection resolves.


Evaluate patients for tuberculosis (TB) infection prior to initiating treatment with BIMZELX. Avoid the use of BIMZELX in patients with active TB infection. Initiate treatment of latent TB prior to administering BIMZELX. Consider anti-TB therapy prior to initiation of BIMZELX in patients with a past history of latent or active TB in whom an adequate course of treatment cannot be confirmed. Closely monitor patients for signs and symptoms of active TB during and after treatment.

Liver Biochemical Abnormalities

Elevated serum transaminases were reported in clinical trials with BIMZELX. Test liver enzymes, alkaline phosphatase and bilirubin at baseline, periodically during treatment with BIMZELX and according to routine patient management. If treatment-related increases in liver enzymes occur and drug-induced liver injury is suspected, interrupt BIMZELX until a diagnosis of liver injury is excluded. Permanently discontinue use of BIMZELX in patients with causally associated combined elevations of transaminases and bilirubin. Avoid use of BIMZELX in patients with acute liver disease or cirrhosis.

Inflammatory Bowel Disease

Cases of inflammatory bowel disease (IBD) have been reported in patients treated with IL-17 inhibitors, including BIMZELX. Avoid use of BIMZELX in patients with active IBD. During BIMZELX treatment, monitor patients for signs and symptoms of IBD and discontinue treatment if new onset or worsening of signs and symptoms occurs.


Prior to initiating therapy with BIMZELX, complete all age-appropriate vaccinations according to current immunization guidelines. Avoid the use of live vaccines in patients treated with BIMZELX.


Most common adverse reactions (≥ 1%) are upper respiratory infections, oral candidiasis, headache, injection site reactions, tinea infections, gastroenteritis, Herpes Simplex infections, acne, folliculitis, other Candida infections, and fatigue.


1. BIMZELX® [prescribing information]. Smyrna, GA: UCB, Inc. 2. Gordon KB, et al. Lancet. 2021;397(10273):475-486. 3. Reich K, et al. N Engl J Med. 2021;385(2):142-152. 4. Iznardo H, et al. Ther Adv Chronic Dis. 2021; 12:20406223211037846. 5. Vidal S, et al. Int J Mol Sci. 2021;22(13):6740.